55.92
price down icon0.94%   -0.53
after-market Dopo l'orario di chiusura: 55.91 -0.01 -0.02%
loading
Precedente Chiudi:
$56.45
Aprire:
$56.49
Volume 24 ore:
1.05M
Relative Volume:
0.42
Capitalizzazione di mercato:
$6.89B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
18.52
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-3.00%
1M Prestazione:
+5.89%
6M Prestazione:
-0.04%
1 anno Prestazione:
+3.48%
Intervallo 1D:
Value
$55.64
$56.66
Intervallo di 1 settimana:
Value
$55.64
$58.56
Portata 52W:
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Nome
Halozyme Therapeutics Inc
Name
Telefono
(858) 794-8889
Name
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Dipendente
350
Name
Cinguettio
@halozymeinc
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
HALO's Discussions on Twitter

Confronta HALO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
55.92 7.10B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-10 Ripresa Goldman Neutral
2025-05-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-05-13 Downgrade Leerink Partners Market Perform → Underperform
2024-10-07 Downgrade Wells Fargo Overweight → Equal Weight
2024-09-19 Downgrade JP Morgan Overweight → Neutral
2024-06-07 Downgrade Piper Sandler Overweight → Neutral
2024-02-29 Iniziato TD Cowen Outperform
2023-07-24 Downgrade Goldman Buy → Neutral
2023-07-24 Iniziato H.C. Wainwright Buy
2023-05-10 Aggiornamento Piper Sandler Neutral → Overweight
2023-03-27 Ripresa Berenberg Buy
2023-03-16 Downgrade SVB Securities Outperform → Market Perform
2022-12-21 Ripresa Morgan Stanley Overweight
2022-11-28 Iniziato Wells Fargo Overweight
2022-09-09 Iniziato Morgan Stanley Overweight
2022-05-23 Iniziato SVB Leerink Outperform
2021-06-14 Iniziato Evercore ISI Outperform
2021-05-17 Iniziato SVB Leerink Outperform
2021-05-11 Downgrade Piper Sandler Overweight → Neutral
2021-01-21 Reiterato The Benchmark Company Buy
2020-12-17 Iniziato Berenberg Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-07-01 Iniziato The Benchmark Company Buy
2020-02-05 Aggiornamento Piper Sandler Neutral → Overweight
2020-01-09 Aggiornamento BMO Capital Markets Market Perform → Outperform
2020-01-08 Iniziato Goldman Buy
2019-11-05 Aggiornamento Barclays Underweight → Equal Weight
2018-10-19 Ripresa Piper Jaffray Neutral
2018-05-11 Downgrade Barclays Equal Weight → Underweight
2018-01-24 Iniziato Goldman Neutral
2017-10-16 Reiterato Piper Jaffray Overweight
2017-01-06 Downgrade Citigroup Buy → Neutral
2016-11-03 Iniziato Deutsche Bank Buy
2015-12-04 Iniziato Wells Fargo Outperform
2015-11-18 Iniziato Citigroup Buy
2015-09-22 Iniziato Barclays Overweight
2015-06-22 Reiterato JP Morgan Overweight
2015-03-03 Reiterato UBS Buy
2015-02-18 Reiterato MLV & Co Buy
2015-01-08 Reiterato MLV & Co Buy
Mostra tutto

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

pulisher
Jul 21, 2025

What analysts say about Halozyme Therapeutics Inc. stockExceptional profit margins - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Halozyme Therapeutics Inc. stock priceExplosive capital gains - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Halozyme Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Beginners Guide - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 17, 2025

Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat

Jul 16, 2025
pulisher
Jul 16, 2025

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru

Jul 16, 2025
pulisher
Jul 16, 2025

Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Halozyme Therapeutics' strategic adoption - MarketScreener

Jul 16, 2025
pulisher
Jul 14, 2025

Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 11, 2025

Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus

Jul 10, 2025
pulisher
Jul 07, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga

Jul 07, 2025
pulisher
Jul 06, 2025

Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress

Jul 06, 2025
pulisher
Jul 04, 2025

Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN

Jul 04, 2025
pulisher
Jul 04, 2025

Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 03, 2025
pulisher
Jul 01, 2025

Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa

Jun 30, 2025
pulisher
Jun 30, 2025

Halozyme therapeutics added to Russell 1000 index - Investing.com

Jun 30, 2025
pulisher
Jun 21, 2025

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve

Jun 21, 2025
pulisher
Jun 20, 2025

Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan

Jun 20, 2025
pulisher
Jun 18, 2025

Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st

Jun 18, 2025
pulisher
Jun 16, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance

Jun 16, 2025
pulisher
Jun 15, 2025

Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha

Jun 15, 2025
pulisher
Jun 12, 2025

Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Merck gains U.S. patent office support in Keytruda dispute - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025

Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Capitalizzazione:     |  Volume (24 ore):